| UHC Surest Medical and Drug | FcRn Blockers (Rystiggo®, Vyvgart®, & Vyvgart Hytrulo®) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Surest Medical and Drug | FDA Cleared or Approved Companion Diagnostic Testing - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Gamifant® (Emapalumab-Lzsg) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Gastrointestinal Motility Disorders, Diagnosis and Treatment - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Gender Dysphoria Treatment - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Genetic Testing for Cardiac Disease - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Genetic Testing for Hereditary Cancer - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Glaucoma Surgical Treatments - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Gynecomastia Surgery - Commercial and Individual Exchange Medical Policy | 2026-01-01 |